Suven Gets Two Product Patents from New Zealand, Norway | CORPORATE ETHOS

Suven Gets Two Product Patents from New Zealand, Norway

By: | May 22, 2018

May 22: Hyderabad-based biopharma major Suven Life Sciences Ltd on Tuesday announced that the company has been granted one product patent from New Zealand (728907) and another one product patent from Norway (341958) corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2034 and 2027 respectively.

According to the company, the granted claims of the patents include the class of selective 5HT6 compounds and are being developed as therapeutic agents for major depressive disorders and for the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia respectively.

“We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally,” said Venkat Jasti, CEO of Suven.

Suven shares were trading at Rs 186, up 3.08% from the previous closing of Rs 180.45, on BSE at 12.19 pm today.